ClinicalTrials.gg
CompletedNCT00190658Updated Dec 20, 2010

Somatropin Treatment in Patients With SHOX Deficiency and Turner Syndrome

A Phase 3 interventional study of Somatropin (rDNA origin) for injection in Failure to Thrive, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 3 Years and older. Per ClinicalTrials.gov, last updated 2010-12-20.

Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
3 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 30 studies in Failure to Thrive with a site in United States — 4 open to participants now, 7 under way, 2 of them phase 3. Failure to Thrive · United States.

Enrollment
12th of 23
75 · median 75
Started
2000
the only one that year
Phase 3
7 of 30
2 open now
Registered
2nd of 30
by date
Lead sponsor
1 of 30
Eli Lilly and Company

Among the 30 studies in Failure to Thrive with a site in United States, this one is the 12th largest by enrollment of the 23 interventional ones that give a count, is the only one that started in 2000, is one of 7 in phase 3, and was the 2nd registered.

Failure to Thrive

84 studies on the registry are indexed under Failure to Thrive; 12 are open to participants now.

Browse Failure to Thrive studies →

Open to participants now

4 of the 30 studies in Failure to Thrive with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Failure to Thrive studies recruiting now, 1 sets no upper age limit and 4 stop at 75 or younger; 5 take children under 18; 1 takes healthy volunteers.

This study: 3 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 30 studies in Failure to Thrive with a site in United States, or all of them as a file.
02

Study summary

This clinical trial will compare the mean first year height velocity of somatropin-treated prepubertal patients with SHOX deficiency with the height velocity of a control group of untreated prepubertal patients with SHOX deficiency. Both groups will be compared to a somatropin-treated group of girls with Turner syndrome. After the second year patients in the control group have the option to receive treatment as well. All patients will optionally be treated until they achieved adult height.

03

Conditions studied

  • Failure to Thrive

Browse trials for

04

Who can participate

Ages eligible
3 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Turner Syndrome or SHOX disorder
  • SHOX: bone age greater than 10 years for boys, greater than 8 years for girls, Turner: bone age greater than 9 years
  • Height below 3rd percentile or height below 10th percentile and growth velocity below 25th percentile
  • Prepubertal: For girls, Tanner stage 1, for boys Tanner stage 1 and testicular volume no more than 2 mL

Exclusion criteria

Exclusion Criteria:

  • GH deficiency or known insensitivity
  • Evidence of tumor activity
  • Diabetes mellitus or history of impaired glucose tolerance
  • Any severe illness known to interfere growth
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants

Interventions

06

What researchers measure

Primary outcomes

  1. Comparison of first year height velocity of somatropin-treated versus non-treated patients with SHOX deficiency.

Secondary outcomes

  1. Comparison of second year height velocity of somatropin-treated versus non-treated patients with SHOX deficiency.

  2. Non inferiority to somatropin treated patients with Turner syndrome

  3. Adult height of treated patients

07

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Philadelphia, Pennsylvania, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2000, a primary completion of Jul 2004 and a completion of Sep 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2005
First posted
Sep 19, 2005
Start
Feb 2000
Primary completionActual
Jul 2004
CompletionActual
Sep 2010
Last update
Dec 20, 2010
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 20, 2010, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00190658
First posted
Sep 19, 2005
Start date
Feb 2000
Primary completion
Jul 2004
Completion
Sep 2010
Last update
Dec 20, 2010

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study chair · Eli Lilly and Company
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion